ctDNA Test is Predictive of Adjuvant Atezolizumab Benefit in MIBC
Patients with muscle-invasive bladder cancer with a positive Signatera test displayed a significant improvement in disease-free and overall survival.
Previous Post
More Employers Offer Preventive Drug Lists Over Time
Next Post
STAT+: Conflicts among CDC and FDA vaccine panel members are not as numerous as you think, study finds
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago